Sesamin inhibits lipopolysaccharide-induced proliferation and invasion through the p38-MAPK and NF-κB signaling pathways in prostate cancer cells

PEIYUAN XU, FEI CAI, XIAOFEI LIU and LELE GUO

Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China

Received December 5, 2014; Accepted March 5, 2015

DOI: 10.3892/or.2015.3888

Abstract. Sesamin, a lipid-soluble lignan, is one of the major constituents of sesame. Previous studies have reported that sesamin induces growth inhibition in human cancer cells, particularly prostate cancer cells. In the present study, we mainly explored the mechanism underlying the protective effect of sesamin on prostate cancer cell proliferation and invasion induced by lipopolysaccharide (LPS). We found that the proliferation of PC3 cells, as determined using the MTT assay, and the expression of cyclin D1, COX-2, Bcl-2 and survivin proteins elevated by LPS were distinctly inhibited by sesamin in a dose-dependent manner. Meanwhile, the ability of PC3 cell invasion, as determined using the Transwell assay and the expression of matrix metalloproteinase 9 (MMP-9), intercellular adhesion molecule-1 (ICAM-1) and vascular endothelial growth factor (VEGF) proteins increased by LPS were obviously reduced by sesamin in a dose-dependent manner. In addition, the accumulation of TGF-α and interleukin-6 (IL-6) production induced by LPS was shown to be via the p38 mitogen-activated protein kinase (p38-MAPK) and NF-κB signaling pathways, which may be one of the mechanisms of the anticancer activity of this sesamin agent in prostate cancer cells.

Introduction

Prostate cancer is the second most commonly diagnosed cancer among Chinese-American males, contributing to the overall cancer burden in this population (1-3). Large increases in both the incidence and mortality rates of prostate cancer are noted for all countries including low-risk populations, but substantial differences exist between countries. According to previous research, genetic, dietary, lifestyle and environmental factors are considered to play an influential role in the etiology of prostate cancer development (2,4).

Lipopolysaccharide (LPS) is a representative strong stimulator of inflammation and has been demonstrated to be associated with various steps in chronic inflammation, such as altering cytokine levels by stimulating inflammatory cells in the tumor microenvironment (5). LPS exposure can also lead to carcinogenesis, induce tumor cell proliferation and survival, facilitate invasion and metastasis, and promote angiogenesis (6-8). For example, LPS can promote prostate cancer PC3 cell migration (9) by inducing the secretion of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) (10), serum levels of which are correlated with the extent of disease in patients with prostate cancer (11). TNF-α has been frequently detected in biopsies from ovarian, renal and breast cancer (12,13) and IL-6 also exhibits a strong association with many types of cancer (14-18). Moreover, research suggests that LPS plays an accelerative role in mediating epithelial-mesenchymal transition (EMT), which has been proposed as a key process in cancer progression with increased migration and invasiveness (19), by modifying the nuclear factor (NK)-κB signaling pathway in breast cancer cells (20). Hence, we speculated that LPS may promote prostate cancer cell proliferation and invasion and tumor progression.
The effect of dietary-derived inhibitory factors on cancer cell invasion and progression have been investigated, such as curcumin (20), anthocyanins from fruits of *Vitis coignetiae* Pulliat (21), green tea polyphenols (22), and lycopene and β-carotene from fruits and vegetables (23). Sesamin, a lignan component from sesame oil, is considered as a common but healthy food with antihypertensive and antioxidative activities. According to previous studies, the potential anticancer effects of food-derived sesamin on human cancer, including breast and colon cancer, hepatocellular carcinoma, and lung cancer are well documented (24-28).

Moreover, sesamin plays an inhibitory role in human prostate cancer cell proliferation (29), implying its potential anticancer application. However, the nature of the growth inhibitory mechanism remains unknown, and the effect of sesamin on prostate cancer cell invasion stimulated by LPS also remains unclear. In the present study, we mainly explored the protective effect of sesamin on the development of prostate cancer cell invasion and tumor progression induced by LPS.

Materials and methods

**Mouse treatment and cell culture.** Male BALB/c nude mice, aged 6-8 weeks (20±2 g), were purchased from Belda Biomedical Science and Technology Co., Ltd. (Suzhou, China). The mice were maintained and used in strict accordance with international standards of animal care guidelines. All experimental procedures were carried out in accordance with the regulations of the Zhengzhou University Committee on Ethics in the Care and Use of Laboratory Animals and were approved by the University Committee for Animal Experiments.

Human prostate cancer cell line PC3 was purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). PC3 cells were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (both from Gibco, Rockville, MD, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin (Life Technologies, Rockville, MD, USA), in a humidified atmosphere of 5% CO₂, 95% air at 37°C. Sesamin was dissolved initially in dimethyl sulfoxide (DMSO), stored as small aliquots at -20°C, then thawed and diluted in a cell culture medium as required for the final concentration of 0, 10, 50, or 100 µg/ml.

**MTT assay.** PC3 cells were seeded into 96-well plates (Corning Inc., Corning, NY, USA) at a density of 5x10⁵ cells/well in RPMI-1640 medium with 10% FBS. After 24 h, the cells were pre-incubated with 0, 10 (S10), 50 (S50) or 100 (S100) µg/ml of sesamin, for 1 h before treatment with 1 µg/ml of LPS (both from Sigma-Aldrich, St Louis, MO, USA) at 37°C in 5% of CO₂. Next, 24 or 48 h later, 20 µl of modified tetrazolium salt 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium-bromide (MTT, 5 mg/ml; Sigma-Aldrich) was added to each well and samples were incubated at 37°C for 4 h. Then the supernatant was carefully removed and 100 µl of DMSO (Sigma-Aldrich) was added to lyse the cells. After the dark-blue MTT crystals dissolved, the absorbance was measured at 490 nm using a Benchmark microplate reader (Bio-Rad, Hercules, CA, USA).

**Invasion assay.** In regards to the Transwell system, Matrigel-coated 24-well Transwell chambers with 8.0-µm polycarbonate filters (Corning Inc.) were used for the *in vitro* invasion assay. Here, 1x10⁵ cells/300 µl were suspended in serum-free RPMI-1640 medium in the upper chamber of each well, and the lower well of each chamber was filled with 750 µl RPMI-1640 medium supplemented with 15% of FBS. LPS (1 µg/ml) and sesamin (0, 10, 50 and 100 µg/ml) were added to both the upper and the lower chambers as described above. After 24 h of treatment, the filters were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet (both from Sigma-Aldrich). Then, the number of invasive cells in at least five randomly selected microscope fields was counted and analyzed statistically.

**Cytokine assay.** PC3 cells were cultured in 6-well plates (Corning Inc.) at a density of 4x10⁵ cells/well in RPMI-1640 medium. LPS (1 µg/ml) and sesamin (0, 10, 50 and 100 µg/ml) were added as described previously. Conditioned medium was collected over 48 h. Cytokines, including TNF-α and IL-6, contained in the conditioned medium were analyzed in triplicate using a sandwich-type enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The absorbance at 450 nm was determined using a microplate reader (Bio-Rad).

**p38-siRNA transfection.** For siRNA transfection, PC3 cells were seeded in 6-well plates at a density of 4x10⁵ cells/well and transfected on the following day with p38-siRNA (25 nM; Cell Signaling Technology, Beverly, MA, USA) or the non-silencing control siRNA (si-NS, 25 nM), as indicated above. Protein concentrations of the cell lysates were determined by the bicinchoninic acid assay (BCA; Thermo Scientific, Rockford, IL, USA) and equal amounts of protein were loaded onto sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), before being transferred to PVDF membranes (Millipore Corp., Bedford, MA, USA), and then processed according to the standard instructions. The antibodies used were rabbit anti-human phospho-p38 mitogen-activated protein kinase (p38-MAPK) (Thr180/Tyr182) monoclonal antibody (#4631) and rabbit anti-p38-MAPK polyclonal antibody (#9212) (both from Cell Signaling Technology); mouse anti-human cyclin D1 monoclonal antibody (sc20044), goat anti-COX-2 polyclonal antibody (sc23983), mouse anti-human Bcl-2 monoclonal antibody (sc509), rabbit anti-survivin polyclonal antibody (sc10811), mouse anti-human matrix metalloproteinase 9 (MMP-9) monoclonal antibody (sc21733), mouse anti-human intercellular adhesion molecule-1 (ICAM-1) monoclonal antibody (sc107), mouse anti-human vascular...
endothelial growth factor (VEGF) monoclonal antibody (sc7269) and rabbit anti-β-actin polyclonal antibody (sc130657) (dilution, 1:1,000) (all from Santa Cruz Biotechnology, Santa Cruz, CA, USA). The secondary antibodies were anti-rabbit or anti-mouse immunoglobulin G conjugated to horseradish peroxidase (dilution, 1:5,000; Beyotime). Signals were detected by enhanced chemiluminescence (ECL) reagent (Beyotime). The absorbance values of target proteins and data analysis were performed using Gel-Pro Analyzer version 4.0 software (Media Cybernetics, Silver Spring, MD, USA).

NF-κB assay. Cultured PC3 cells were seeded in 6-well plates at a density of 4x10^5 cells/well as indicated, respectively. Stimulation of LPS (1 µg/ml), sesamin (100 µg/ml) or SB203580 (10 nM) was performed as described above after p38-siRNA/p38-siNS transfection or not. To prepare nuclear extracts for the NF-κB assay, the cells were washed with cold PBS, collected by centrifugation, resuspended in hypotonic lysis buffer, incubated on ice for 15 min and then mixed with 0.75% Nonidet P-40 (NP-40) solution. The nuclear extract was collected and centrifuged at 4,000 x g for 2 min, and stored at -80˚C. Protein concentration was determined by the BCA assay. Then, NF-κB activity in nuclear extracts was analyzed by a NF-κB p65 ActivELISA kit (Imgenex, San Diego, CA, USA) according to the manufacturer's instructions. The absorbance was determined using a microplate reader set at 405 nm.

In vivo assay. Cultured PC3 cells were washed 3 times with PBS. For this, 1x10^7 cells/100 µl PBS were inoculated subcutaneously at the right armpit of BALB/c nude mice. After 7 days, the mice were administered PBS (control) only, LPS (2 mg/kg) only or sesamin (10 mg/kg) and SB203580 (10 mg/kg), respectively before injection with LPS (n=4 per group). The sesamin and SB203580 were injected every 3 days, respectively. Twenty-one days later, all mice from the different groups were sacrificed. Caliper measurement of tumor volume was conducted every other day, and the tumor volume (V) was calculated according to the following formula: V = (largest diameter) x (smallest diameter)²/2.

Statistical analysis. Results are expressed as the mean ± SD representative of three individual experiments performed in triplicate. Statistical analysis was performed by the Student's t-test and ANOVA test. P<0.05 was considered to be statistically significant compared to the respective control.

Results

Sesamin inhibits LPS-induced cell proliferation. To examine whether sesamin modulates prostate cancer cell proliferation stimulated by LPS, we used the MTT assay and further investigated the effect of sesamin (0, 10, 50 and 100 µg/ml) on the expression of proliferative-related proteins, cyclin D1 and COX-2, in the LPS-stimulated PC3 cells. We found that the proliferation rate of PC3 cells was distinctly promoted by LPS, but was distinctly suppressed by sesamin pretreatment in a dose- and time-dependent manner (Fig. 1A). Moreover, sesamin pretreatment dose-dependently downregulated the expression of cyclin D1 and COX-2 gene products induced by LPS (Fig. 1B and C). Therefore, sesamin had a negative effect on the cell proliferation and the expression of tumor cell-proliferative proteins induced by LPS in the PC3 cells.

Sesamin inhibits the expression of Bcl-2 and survivin proteins induced by LPS. To evaluate the effect of LPS and sesamin on prostate cancer cell apoptosis, we determined the expression of Bcl-2 and survivin proteins related to tumor cell survival with sesamin pretreatment under LPS stimulation. The results indicated that sesamin pretreatment dose-dependently inhibited the expression of Bcl-2 and survivin proteins induced by LPS (Fig. 2), thus implying that the possible mechanism for the anti-apoptotic effect of sesamin may be through the downregulation of cell survival proteins, including Bcl-2 and survivin.

Sesamin inhibits LPS-induced cell invasion. To determine the effect of LPS and sesamin on prostate cancer cell invasion,
we used the Matrigel invasion assay and western blotting of invasion-related proteins, which are known to be involved in cancer cell invasion, adhesion and angiogenesis. The results revealed that the invasive ability of the PC3 cells was markedly promoted by LPS and further markedly and dose-dependently inhibited by sesamin pretreatment (Fig. 3A). More importantly, sesamin pretreatment dose-dependently suppressed the increased expression of MMP-9, ICAM-1 and VEGF proteins induced by LPS (Fig. 3B and C). Thus, these data confirmed the inhibitory role of sesamin in the invasiveness of prostate cancer and on the expression of tumor cell metastatic proteins.

Sesamin inhibits LPS-induced cytokine production. To investigate the effect of LPS and sesamin on the secretion of TGF-α and IL-6 in PC3 cells, we detected the concentration of TGF-α and IL-6 production in the culture supernatant of PC3 cells under LPS stimulation with sesamin pretreatment. The MTT assay revealed that there was no toxic impact on cells following these processes for 48 h. The data revealed that the accumulation of TGF-α and IL-6 production induced by LPS in conditioned medium was decreased dose-dependently following sesamin pretreatment in PC3 cells (Fig. 4).

Sesamin inhibits LPS-induced p38-MAPK activation. To examine whether the p38-MAPK signaling pathway is involved in the enhanced cell proliferation and invasion in response to TNF-α and IL-6 accumulation, we detected the p-p38 and p38 proteins following either sesamin (100 µg/ml) or SB203580 (10 nM) pretreatment or p38-siRNA/p38-siNS transfection in the LPS-stimulated PC3 cells. The results revealed that sesamin pretreatment inhibited the phosphorylation of the p38 protein increased by LPS stimulation, and pretreatment with SB203580, a specific inhibitor of p38-MAPK, showed the same degree of inhibition (Fig. 5A and B). In addition, compared to the control and p38-siNS transfection group, pretreatment with p38-siRNA transfection obviously decreased both p-p38 and p38 proteins under LPS stimulation.

Sesamin inhibits LPS-induced NF-κB activity. Importantly, to assess the effect of sesamin on NF-κB activity induced by LPS, we used SB203580 pretreatment or p38-siRNA/p38-siNS transfection to investigate the action mechanism of sesamin on NF-κB activity in the LPS-stimulated PC3 cells. Similar
to the inhibitory effect of SB203580 and p38-siRNA, sesamin pretreatment clearly suppressed the constitutive and inducible NF-κB activity at a concentration of 100 µg/ml (Fig. 6). Therefore, it can be concluded that LPS-induced translocation of the NF-κB p65 subunit to the nucleus could be inhibited by sesamin to some extent.

**Sesamin reduces PC3 cell-derived tumor growth enhanced by LPS in vivo.** To evaluate the effect of sesamin on tumor growth in vivo, we used the SB203580 pretreatment to determine the LPS-stimulated tumor progression derived from PC3 cells in BALB/c nude mice. Compared to the control group, the tumor volume in the LPS pretreatment group was distinctly larger, and the tumor volume in the LPS plus sesamin group was relatively smaller after 14 days post-incubation (Fig. 7). The results illustrated that either sesamin or SB203580 treatment could obviously inhibit PC3 cell-derived tumor growth induced by LPS in vivo.

**Discussion**

Prostate cancer is a relatively common cancer among males worldwide, and an increasing number of men are at a high risk due to various reasons, including dietary and environmental factors. Sesamin, a type of phytoestrogen, is a lignan that is found abundantly in sesame oil and potentially possesses multiple functions, such as antioxidant, anti-inflammatory, and anticancer activities. Considering this, the present study mainly focused on the protective effect of sesamin on the development of prostate cancer cell invasion and tumor progression under LPS stimulation.

Research has shown that sesamin induces arrest at the G1 phase of the cell cycle in human breast cancer MCF-7
cells (26) and inhibits cell proliferation in various types of tumor cells (29). Sesamin also suppresses TNF-induced expression of cyclin D1, COX-2 and cell survival gene products including Bcl-2 and survivin proteins in human chronic myeloid leukemia cells (29). In addition, the COX-2 protein is reported to be overexpressed in lung tumor tissues (30) and the inhibition of COX-2 can arrest progression of the cell cycle in prostate cancer cells (31). In addition, LPS promotes cell survival and proliferation in hepatocellular carcinoma cells (32) and significantly activates the expression and activity of COX-2 in human colon carcinoma cells (33). In the present study, our data indicated that sesamin pretreatment suppressed LPS-induced PC3 cell proliferation and the expression of cyclin D1, COX-2, Bcl-2 and survivin proteins, which are correlated with cell proliferation, the synthesis and secretion of prostaglandin E2 and cell survival.

Moreover, sesamin was previously found to inhibit the levels of TNF-α and IL-6 induced by macrophages, and reduced the expression of VEGF and MMP-9 proteins, thus suppressing cell migration and exhibiting anti-angiogenic activity in human breast cancer MCF-7 cells (34). Our results revealed that the accumulation of TNF-α and IL-6 was enhanced by LPS and was suppressed to a lesser degree by sesamin pretreatment in a dose-dependent manner in PC3 cells. Furthermore, sesamin also showed a distinct negative effect on LPS-induced PC3 cell invasion and the expression of MMP-9, ICAM-1 and VEGF proteins, thus implying the potential role of sesamin in the suppression of human prostate cancer cell invasion, adhesion and the prevention of tumor angiogenesis. Hence, we conclude that sesamin downregulates the abnormal induction of related inflammatory cytokines such as TNF-α and IL-6 induced by LPS, and in turn, inhibits the reinforced induction of proteins which are associated with cell invasion and progression in prostate cancer PC3 cells.

In addition, an abnormality in levels of these cytokines has also been shown as one of the major causes of constitutive p38-MAPK signaling pathway and NF-κB activity in cancer cells (34,35). Meanwhile, LPS cytotoxicity is reported to be mediated through the activation of p38-MAPK and NF-κB pathways in hepatocellular carcinoma cells (32). Upon LPS stimulation, the phosphorylation of p38 was detected in human esophageal cancer cells (36). NF-κB activity has been commonly associated with inflammation, carcinogenesis, tumor cell survival, proliferation, invasion and angiogenesis of cancer (29). More importantly, both nuclear levels of NF-κB and p38-MAPK activity were found to be potently inhibited by sesamin via the downregulation of TNF-α and IL-6 in human breast cancer cells (34). Likewise, our research found that sesamin significantly suppressed phosphorylation of the p38 protein and the NF-κB activity induced by LPS in prostate cancer PC3 cells.

Furthermore, SB203580, a specific inhibitor of p38-MAPK, specifically reduces cell proliferation, migration and survival in prostate cancer cells (37), and SB203580 pretreatment of head and neck squamous cell carcinoma cells also reduced cancer growth in tumor xenographs (38). Mouse treated with chronic inhibition of p38-MAPK with SB203580 showed complete absence of osteoblastic growth in the intramedullary space as well as significantly reduced tumor burden (39). In the present study, we used a nude mouse model to investigate the role of the p38-MAPK and NF-κB signaling pathways activated by LPS on inflammation-induced tumor growth by an in vivo assay. Consistently, our research showed that tumor growth was distinctly enhanced in response to LPS and further significantly restrained by sesamin or SB203580 pretreatment in terms of tumor size. In addition, sesamin or SB203580 pretreatment led to distinct reductions in the phosphorylation of p38 protein and NF-κB activity induced by LPS. Meanwhile, cells transfected with p38-siRNA showed the same inhibitory effect, implying the potential role of the p38-MAPK and NF-κB pathways in the sesamin-pretreated PC3 cells.

Collectively, these results demonstrated that sesamin significantly attenuated the expression of TNF-α, IL-6, cyclin D1, COX-2, Bcl-2 and survivin, as well as MMP-9, ICAM-1 and VEGF proteins induced by LPS through the p38-MAPK signaling pathway and NF-κB activation in PC3 cells under LPS stimulation and further inhibited tumor growth in tumors derived from the inoculation of PC3 cells. Thus, the present study showed the suppressive activity of sesamin on prostate cancer cell proliferation and invasion induced by LPS. These findings may assist in the better understanding of the molecular mechanisms of the effects of sesamin on cell invasiveness and tumorigenesis, thus providing a new insight into the effect of sesamin during the progression of human prostate cancer.

References

